Creabilis names Catherine Moukheibir as chairman of the board

Dermatology firm Creabilis has appointed Catherine Moukheibir as chairman of its board of directors.

Moukheiber will head the board as it progresses its lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itching) due to psoriasis.

Commenting on her appointment, Moukheibir said: “I am delighted to have been appointed to lead the Creabilis Board at this important time in the Company's development. 

“The potential of CT327 in the treatment of pruritic conditions is a significant opportunity and the data reported so far demonstrates the power of Creabilis' pipeline and its unique low systemic exposure platform technology.”

Moukheibir has a wide range of experience in aligning corporate goals with financial strategy. 

After an initial career in strategy consulting and investment banking, she held a number of senior management role at European biotech firms including CFO at Movetis, non-executive board member at Ablynx and member of the management board at Innate Pharma.

Last November, Moukheiber was also named as an observer to Zealand's board of directors.